Product Details
Product Details
Product Specification
| Species | Human |
| Antigen | BCMA |
| Synonyms | TNFRSF17,CD269,BCM,BCMA |
| Accession | Q02223-1 |
| Amino Acid Sequence | Met1-Ala54, with C-terminal Human IgG1 Fc &Avi tag |
| Expression System | HEK293 |
| Molecular Weight | 38-45kDa (Reducing) |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Biotin |
| Tag | Human Fc Tag, Avi Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
1.Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi& Saad Z. Usmani: B-cell maturation antigen (BCMA) in multiple myeloma:rationale for targeting and current therapeutic approaches, Leukemia volume 34, pages985–1005 (2020). |
Background
BCMA (The B-cell maturation antigen), alsodesignated as TNFRSF17, belongs to the tumor necrosis factor receptorsuperfamily, which is a family of cytokine receptors. BCMA is encoded by a2.92-kb TNFRSF17 gene located on the short arm of chromosome 16 (16p13.13) andcomposed of 3 exons separated by 2 introns. There are four natural splicevariants of human BCMA that present with different receptor binding affinities,membrane-anchoring ability, and intracellular domain signaling. BCMA mainligands are the cytokines B-cell activating factor and a proliferation-inducingligand. The interaction between BCMA and its ligands activates the NF-κBsignaling pathway that plays an important role in B-cell proliferation andmaturation and is essential for the survival of long-lived bone marrow plasmacells. BCMA is expressed preferentially on mature B cells and has minimalexpression on hematopoietic stem cells or other cell types. The BCMA hasemerged as a central target in multiple myeloma (MM). In preclinical studies,overexpression of BCMA and the interaction with is ligand, aproliferation-inducing ligand (APRIL), was found to promote MM progression invivo and augment MM cell growth and survival through induction of multiplesignaling cascades, including protein kinase B (AKT), MAPK, and nuclear factor(NF)-κB. Additionally, BCMA has been shown to be solubilized at high levels inserum of patients with MM (sBCMA). This form of sBCMA binds to B-cellactivating factor (BAFF). The role of BAFF is to stimulate normal B-cell andplasma cell development; however, this functioning is prevented when it isbound by BCMA in the serum, thereby leading to decreased polyclonal immunoglobulinlevels in patients with MM.
Picture
Picture
SDS-PAGE

ELISA

Immobilized Anti-Human BCMA Monoclonal Antibody (Belantamab) at 2.0μg/mL (100μL/well) can bind Biotinylated BCMA Fc&Avi Tag, Human (Cat. No. UA010461)with EC50 of 4.30-6.13ng/mL.
